Table 1.
Baseline characteristics by cohort (full analysis set).
| Cohort 1 (gBRCAm) (n = 75) | Cohort 2 (sBRCAm) (n = 26) | Cohort 3 (HRD-positive non-BRCAm) (n = 68) | Cohort 4 (HRD-negative) (n = 90) | Unassigneda (n = 13) | Overall (N = 272) | |
|---|---|---|---|---|---|---|
| Median age, years (range) | 61 (42–80) | 71 (50–90) | 64 (38–88) | 69 (35–91) | 72 (45–81) | 66 (35–91) |
| Median time from primary diagnosis, months | 26.1 | 31.7 | 35.4 | 34.5 | 20.9 | 32.4 |
| Median prior lines of chemotherapy, n (range) | 1.0 (1–4) | 2.0 (1–5) | 2.0 (1–4) | 2.0 (1–7) | 1.0 (1–5) | 2.0 (1–7) |
| Histology | ||||||
| Serous | 68 (90.7) | 24 (92.3) | 65 (95.6) | 83 (92.2) | 13 (100.0) | 253 (93.0) |
| Other | 7 (9.3) | 2 (7.7) | 3 (4.4) | 7 (7.8) | 0 | 19 (7.0) |
| Tumor grade | ||||||
| High grade | 51 (68.0) | 21 (80.8) | 53 (77.9) | 67 (74.4) | 13 (100.0) | 205 (75.4) |
| Poorly differentiated (G3) | 21 (28.0) | 5 (19.2) | 13 (19.1) | 18 (20.0) | 0 | 57 (21.0) |
| Moderately differentiated (G2) | 3 (4.0) | 0 | 1 (1.5) | 4 (4.4) | 0 | 8 (2.9) |
| Well differentiated (G1) | 0 | 0 | 1 (1.5) | 0 | 0 | 1 (0.4) |
| Missing | 0 | 0 | 0 | 1 (1.1) | 0 | 1 (0.4) |
| FIGO stage at original diagnosis | ||||||
| I | 5 (6.7) | 3 (11.5) | 0 | 4 (4.4) | 0 | 12 (4.4) |
| II | 5 (6.7) | 1 (3.8) | 4 (5.9) | 5 (5.6) | 0 | 15 (5.5) |
| III | 53 (70.7) | 14 (53.8) | 53 (77.9) | 65 (72.2) | 9 (69.2) | 194 (71.3) |
| IV | 12 (16.0) | 8 (30.8) | 11 (16.2) | 16 (17.8) | 3 (23.1) | 50 (18.4) |
| Missing | 0 | 0 | 0 | 0 | 1 (7.7) | 1 (0.4) |
| ECOG performance status | ||||||
| 0 | 58 (77.3) | 13 (50.0) | 48 (70.6) | 56 (62.2) | 6 (46.2) | 181 (66.5) |
| 1 | 17 (22.7) | 12 (46.2) | 20 (29.4) | 34 (37.8) | 7 (53.8) | 90 (33.1) |
| Missing | 0 | 1 (3.8) | 0 | 0 | 0 | 1 (0.4) |
NOTE. Data are n (%) unless otherwise stated.
BRCAm, BRCA1 and/or BRCA2 mutation; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Gynecology and Obstetrics; gBRCAm, germline BRCAm; HRD, homologous recombination deficiency; sBRCAm, somatic BRCAm.
a
Includes patients who were not assigned to a cohort as they had a Myriad test result of failed or missing.